Last reviewed · How we verify
NCT05071378
Leveraging Family-Based Assets for Black MSM In House Ball Communities
NA trial testing Our Family, Our Voices in HIV I Infection in 168 participants. Status unknown.
30 November 2021
Quick facts
| Lead sponsor | State University of New York - Downstate Medical Center |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 168 |
| Start date | 17 September 2020 |
| Primary completion | 30 November 2021 |
| Estimated completion | 30 November 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Our Family, Our Voices
Conditions studied
- HIV I Infection — all drugs for HIV I Infection →
Sponsor
State University of New York - Downstate Medical Center
Who can join
Adults 18 to 30, any sex, with HIV I Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite the advent of highly effective prevention tools such as HIV pre-exposure prophylaxis (PrEP), Black men who have sex with men (MSM) continue to have the highest incidence of new HIV diagnoses in the US but are least likely to be engaged in care or to be virally suppressed. Many Black MSM face multiple stigmas but some have found refuge in the House Ball Community (HBC)-a national network of Black LGBT kinship commitments (families) that provide (informal) care giving, affirmation and survival skills-building for its members. The HBC is a large, yet underserved, community within the larger LGBT community. The investigators propose to modify a well-established skills-building and HIV prevention best-evidence, group-level intervention for HIV-negative Black MSM, Many Men Many Voices, into a family-based intervention to focus on asset-building for both HIV-negative and HIV-positive Black MSM within HBC families. Many Men Many Voices (3MV) is a six-session, group-level behavioral intervention and is the only "best evidence" intervention for Black MSM. Family-based interventions have shown HIV prevention efficacy; however, 3MV is not a family-based intervention. In 3MV, HIV-negative Black MSM are recruited into artificial group settings with individuals with whom they may have little social relationship. 3MV neither leverages the connections and commitments nor addresses the variability in HIV-status that exists in house ball families. Because Black MSM in the HBC have closer social relationships, 3MV requires adaptation to be more responsive to this social structure and dynamic. The study's goal in this clinical trial planning grant is to prepare for a cluster randomized controlled trial (CRCT) to test the effectiveness of the modified 3MV vs. standard of care in reducing new HIV infections and increasing rates of viral suppression among Black MSM in HBC families. The study's central hypothesis is that a modified 3MV intervention incorporating family asset-building will have an amplifying effect on HIV prevention and treatment outcomes. This study will provide necessary data to design and conduct a full-scale CRCT effectiveness trial of OFOV on HIV prevention and care outcomes in Black MSM. By precision-tailoring an evidence-based intervention for the HBC, the investigators' research to improve HIV testing and care engagement will complement national efforts to End the Epidemic by 2030, especially among Black MSM-the highest priority group for domestic HIV prevention.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05071378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV I Infection
Currently open trials in the same condition.
- NCT06799338 — Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France · recruiting
- NCT06834113 — Impact of Pain From Injectables Antiretroviral Treatments in HIV-1 Patients Based on the Injection Site (Ventrogluteal o · NA · recruiting
- NCT07202936 — Cervical Pre-cancer Treatment Failure Among Women Living With HIV in Zimbabwe · recruiting
- NCT05947890 — Evaluating the Safety and Immunogenicity of MTBVAC · Phase 2 · recruiting
- NCT05110963 — Intervention to Improve HIV Care Retention by Addressing Stigma Stigmatized Environments · NA · active not recruiting
Other State University of New York - Downstate Medical Center trials
Trials by the same sponsor.
- NCT06119152 — Digital Equity for Stroke Approach · NA · unknown
- NCT05796167 — Pimavanserin for Sleep in Parkinson Disease · EARLY_PHASE1 · withdrawn
- NCT04755595 — Combination Facial Aesthetic Treatment in Millennials · Phase 2 · completed
- NCT05439772 — Examining the Effect of Ondansetron on Bowel Prep Success · Phase 4 · completed
- NCT02927405 — Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05071378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by State University of New York - Downstate Medical Center
- Last refreshed: 8 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05071378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing